Anaplastic thyroid carcinoma: review of treatment protocols

被引:91
作者
Tiedje, Vera [1 ]
Stuschke, Martin [2 ]
Weber, Frank [3 ]
Dralle, Henning [3 ]
Moss, Laura [4 ]
Fuehrer, Dagmar [1 ]
机构
[1] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Endocrine Tumour Ctr,Dept Endocrinol Diabetol & M, Essen, Germany
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Radiotherapy, Essen, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Sect Endocrine Surg, Dept Gen Visceral & Transplantat Surg, Essen, Germany
[4] Velindre Canc Ctr, Cardiff, S Glam, Wales
关键词
anaplastic thyroid carcinoma; treatment protocol; radiotherapy; targeted therapy; ASSOCIATION GUIDELINES; SINGLE-INSTITUTION; CANCER; SURVIVAL; CHEMOTHERAPY; MANAGEMENT; BRAF; FOSBRETABULIN; VEMURAFENIB; THERAPY;
D O I
10.1530/ERC-17-0435
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Anaplastic thyroid carcinoma (ATC) is an orphan disease and in most patients fatal. So far no established treatment is available that prolongs survival. Several large retrospective studies have identified negative prognostic markers, analyzed efficacy of multimodal approaches such as radiotherapy with and without concurrent chemotherapy and chemotherapy protocols. Recently, single case reports have suggested some effectiveness of newer therapies targeting single somatic alterations in ATC. Overall, the conclusions that can be drawn from published retrospective studies and the scarce prospective approaches is that new treatment protocols should be developed including surgery, radiotherapy, chemotherapy and targeted therapy approaches and combinational therapy with immunotherapies. These protocols then need to be evaluated prospectively to improve ATC patients' outcome in routine care.
引用
收藏
页码:R153 / R161
页数:9
相关论文
共 47 条
  • [1] Response to Targeted Therapy in BRAF Mutant Anaplastic Thyroid Cancer
    Agarwal, Rishi
    Wang, Jiang
    Wilson, Keith
    Barrett, William
    Morris, John C.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2016, 14 (10): : 1203 - 1207
  • [2] Baek SK, 2016, HEAD NECK-J SCI SPEC, V39, P133
  • [3] A Multiinstitutional Phase 2 Trial of Pazopanib Monotherapy in Advanced Anaplastic Thyroid Cancer
    Bible, Keith C.
    Suman, Vera J.
    Menefee, Michael E.
    Smallridge, Robert C.
    Molina, Julian R.
    Maples, William J.
    Karlin, Nina J.
    Traynor, Anne M.
    Kumar, Priya
    Goh, Boon Cher
    Lim, Wan-Teck
    Bossou, Ayoko R.
    Isham, Crescent R.
    Webster, Kevin P.
    Kukla, Andrea K.
    Bieber, Carolyn
    Burton, Jill K.
    Harris, Pamela
    Erlichman, Charles
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (09) : 3179 - 3184
  • [4] Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer
    Brauner, Eran
    Gunda, Viswanath
    Vanden Borre, Pierre
    Zurakowski, David
    Kim, Yon Seon
    Dennett, Kate Virginia
    Amin, Salma
    Freeman, Gordon James
    Parangi, Sareh
    [J]. ONCOTARGET, 2016, 7 (13) : 17194 - 17211
  • [5] Early Surgery and Survival of Patients with Anaplastic Thyroid Carcinoma: Analysis of a Case Series Referred to a Single Institution Between 1999 and 2012
    Brignardello, Enrico
    Palestini, Nicola
    Felicetti, Francesco
    Castiglione, Anna
    Piovesan, Alessandro
    Gallo, Marco
    Freddi, Milena
    Ricardi, Umberto
    Gasparri, Guido
    Ciccone, Giovannino
    Arvat, Emanuela
    Boccuzzi, Giuseppe
    [J]. THYROID, 2014, 24 (11) : 1600 - 1606
  • [6] Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer
    Cabanillas, Maria E.
    Williams, Michelle D.
    Gunn, G. Brandon
    Weitzman, Steven P.
    Burke, Laura
    Busaidy, Naifa L.
    Ying, Anita K.
    Yiin, Yeh Hung
    William, William N.
    Lu, Charles
    Lai, Stephen Y.
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2017, 39 (07): : 1291 - 1295
  • [7] Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors
    Danilova, Ludmila
    Wang, Hao
    Sunshine, Joel
    Kaunitz, Genevieve J.
    Cottrell, Tricia R.
    Xu, Haiying
    Esandrio, Jessica
    Anders, Robert A.
    Cope, Leslie
    Pardoll, Drew M.
    Drake, Charles G.
    Taube, Janis M.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (48) : E7769 - E7777
  • [8] Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy
    De Crevoisier, R
    Baudin, E
    Bachelot, A
    Leboulleux, S
    Travagli, JP
    Caillou, B
    Schlumberger, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04): : 1137 - 1143
  • [9] German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors
    Dralle, Henning
    Musholt, Thomas J.
    Schabram, Jochen
    Steinmueller, Thomas
    Frilling, Andreja
    Simon, Dietmar
    Goretzki, Peter E.
    Niederle, Bruno
    Scheuba, Christian
    Clerici, Thomas
    Hermann, Michael
    Kussmann, Jochen
    Lorenz, Kerstin
    Nies, Christoph
    Schabram, Peter
    Trupka, Arnold
    Zielke, Andreas
    Karges, Wolfram
    Luster, Markus
    Schmid, Kurt W.
    Vordermark, Dirk
    Schmoll, Hans-Joachim
    Muehlenberg, Reinhard
    Schober, Otmar
    Rimmele, Harald
    Machens, Andreas
    [J]. LANGENBECKS ARCHIVES OF SURGERY, 2013, 398 (03) : 347 - 375
  • [10] Long-term results of radiotherapy in anaplastic thyroid cancer
    Dumke, Anne-Katrin
    Pelz, Tanja
    Vordermark, Dirk
    [J]. RADIATION ONCOLOGY, 2014, 9